OncoMatch/Clinical Trials/NCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Is NCT06733441 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including TLN-254 and TLN-254 for lymphoma.
Treatment: TLN-254 · TLN-254 — The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic treatment
Cohort 1: PTCL that has relapsed after, or not responded to at least one prior systemic treatment regimen
Must have received: systemic treatment
Cohort 2: Relapsed/refractory CTCL which has relapsed after, or not responded to at least two prior systemic treatments
Must have received: antibody-drug conjugate (brentuximab vedotin)
Participants with Anaplastic large cell lymphoma (ALCL) should have received prior brentuximab vedotin treatment.
Cannot have received: systemic anti-cancer treatment
Participants must not have prior systemic anti-cancer treatment less than or equal to (≤) 5 half-lives or 4 weeks prior to study intervention initiation.
Cannot have received: allogeneic stem cell transplant
allogeneic SCT≤90 days prior to study intervention initiation.
Cannot have received: autologous stem cell transplant
autologous SCT ≤60 days prior to study intervention initiation.
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Institute · Stanford, California
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify